BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33279948)

  • 1. HDAC8-dependent deacetylation of PKM2 directs nuclear localization and glycolysis to promote proliferation in hepatocellular carcinoma.
    Zhang R; Shen M; Wu C; Chen Y; Lu J; Li J; Zhao L; Meng H; Zhou X; Huang G; Zhao X; Liu J
    Cell Death Dis; 2020 Dec; 11(12):1036. PubMed ID: 33279948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
    Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
    Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirtuin-mediated deacetylation of hnRNP A1 suppresses glycolysis and growth in hepatocellular carcinoma.
    Yang H; Zhu R; Zhao X; Liu L; Zhou Z; Zhao L; Liang B; Ma W; Zhao J; Liu J; Huang G
    Oncogene; 2019 Jun; 38(25):4915-4931. PubMed ID: 30858544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
    Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
    J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
    Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
    PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSP50 promotes the Warburg effect and hepatocyte proliferation via regulating PKM2 acetylation.
    Gao F; Zhang X; Wang S; Zheng L; Sun Y; Wang G; Song Z; Bao Y
    Cell Death Dis; 2021 May; 12(6):517. PubMed ID: 34016961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway.
    Wang Q; Lu D; Fan L; Li Y; Liu Y; Yu H; Wang H; Liu J; Sun G
    Int J Mol Med; 2019 Jan; 43(1):475-488. PubMed ID: 30365092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
    Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
    J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Pyruvate Kinase Type M2 (PKM2) Promotes Ovarian Cancer Cell Growth and Survival Via Regulation of Cell Cycle Progression Related with Upregulated CCND1 and Downregulated CDKN1A Expression.
    Zheng B; Liu F; Zeng L; Geng L; Ouyang X; Wang K; Huang Q
    Med Sci Monit; 2018 May; 24():3103-3112. PubMed ID: 29752805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions.
    Bhardwaj A; Das S
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E538-47. PubMed ID: 26787900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
    Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
    PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2,3'4,4',5-Pentachlorobiphenyl induces hepatocellular carcinoma cell proliferation through pyruvate kinase M2-dependent glycolysis.
    Liang W; Zhang Y; Song L; Li Z
    Toxicol Lett; 2019 Oct; 313():108-119. PubMed ID: 31251971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
    Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
    Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.
    Li W; Qiu Y; Hao J; Zhao C; Deng X; Shu G
    Food Chem Toxicol; 2018 Nov; 121():156-165. PubMed ID: 30171973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis.
    Yang W; Xia Y; Hawke D; Li X; Liang J; Xing D; Aldape K; Hunter T; Alfred Yung WK; Lu Z
    Cell; 2012 Aug; 150(4):685-96. PubMed ID: 22901803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
    Jung Y; Jang YJ; Kang MH; Park YS; Oh SJ; Lee DC; Xie Z; Yoo HS; Park KC; Yeom YI
    Mol Cells; 2013 Apr; 35(4):335-41. PubMed ID: 23515579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism.
    Shiroki T; Yokoyama M; Tanuma N; Maejima R; Tamai K; Yamaguchi K; Oikawa T; Noguchi T; Miura K; Fujiya T; Shima H; Sato I; Murata-Kamiya N; Hatakeyama M; Iijima K; Shimosegawa T; Satoh K
    Cancer Sci; 2017 May; 108(5):931-940. PubMed ID: 28235245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyruvate kinase M2 interacts with nuclear sterol regulatory element-binding protein 1a and thereby activates lipogenesis and cell proliferation in hepatocellular carcinoma.
    Zhao X; Zhao L; Yang H; Li J; Min X; Yang F; Liu J; Huang G
    J Biol Chem; 2018 Apr; 293(17):6623-6634. PubMed ID: 29514980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
    Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
    Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.